The data herein also indicate that blocking the interleukin 21/4 and/or CD40L might be of therapeutic interest in CLL, especially in the light of the minimal toxicity of such approaches in type 1 diabetes, asthma and multiple sclerosis therapy trials, respectively [57–59]. Here, IL21 is linked to asthma.